Supplementary Materialscells-09-02443-s001. data repositories of FLT3 ITD-positive AML patients, we identified activated cytokine networks that affect the formation of the haematopoietic niche by controlling osteoclastogenesis and osteoblast functions. In addition, aberrant oncogenic FLT3 Bismuth Subsalicylate signalling of osteogenesis-specific cytokines affects survival of AML patients and may be used for prognosis. Thus, these data highlight the intimate crosstalk between leukaemic and osteogenic cells within the osteohaematopoietic niche. 0.05. Stars indicate as follows * 0.05; ** 0.01, *** 0.001, **** 0.0001; n.d., not determined. = 0.52?2.03 = 0.24* ?2.42, = 0.049?1.66, = 0.33205290_s_at?2.70, = 0.14?1.86, = 0.30?2.40, = 0.051?1.87, = 0.27 BMP6 206176_at?2.04, = 0.30?2.46, = 0.12?1.0, = 0.44?2.27, = 0.16215042_at0.25, = 0.94?0.34, = 0.88?1.22, = 0.34?1.51, = 0.38 BMP7 209590_at?0.76, = 0.78?1.67, = 0.37* ?3.81, = 0.02?0.51, = 0.8209591_s_at0.50, = 0.860.99, = 0.61?1.92, = 0.120.56, = 0.78 CSF1 = 0.981.12, = 0.591.88, = 0.131.04, = 0.59210557_x_at?0.88, = 0.74?0.04, = 0.99?1.52, = 0.23?0.11, = 0.7964211839_s_at?0.89, = 0.740.04, = 0.98n.d.?0.77, = 0.7694207082_at?0.59, = 0.84?0.038, = 0.99?0.62, = 0.620.54, = 0.79 CSFR1 203104:at?1.85, = 0.37?0.74, = 0.72* 2.66, = 0.030.41, = 0.58 CTHRC1 225681_atn.d. ?1.63, = 0.37n.d. ?2.23, = 0.17 CXCL12 203666_at?1.16, = 0.63?1.71, = 0.34* ?2.42, = 0.048?0.28, = 0.89209687_at?1.66, = 0.43?1.33, = 0.50?1.48, = 0.23?0.51, = 0.80 DKK1 204602_at?0.0036, = 0.99?1.86, = 0.29* ?3.02, = 0.0130.85, = 0.65 FGF23 221166_at?0.88, = 0.74?1.64, = 0.37** ?3.55, = 0.004?0.90, = 0.64 FLT3 206674_at3.32, = 0.057*** 4.67, = 0.00066** 3.66, = 0.00293.27, 0.05 FLT3LG 206980_s_at?2.21, = 0.25?1.82, = 0.300.34, = 0.81?1.77, = 0.29210607_at?2.17, = 0.26* ?2.99, = 0.045?0.03, = 0.98?2.31, = 0.15 IL12A 207160_at* 3.53, = 0.044*** 5.22, = 0.00013**** 6.38, = 1.49e-63.32, = 0.05 IL-1 39402_at?0.53, = 0.86?0.67, = 0.751.45, = 0.250.83, = 0.66 KITLG (SCF) 207029_a0.45, = 0.871.37, = 0.49?0.73, = 0.590.15, = 0.95211124_s_a1.22, = 0.622.61, = 0.10?0.63, = 0.640.36, = 0.87 Kremen2 219692_at?1.0, = 0.70?0.81, = 0.69?2.00, = 0.110.85, = 0.65 MMP9 203936_s_at?1.26, = 0.59?2.65, = 0.08?2.26, = 0.06?1.59, = 0.35 OSCAR 1554503_a_atn.d.1.49, = 0.43n.d. 1.82, = 0.27 Runx2 216994_s_at1.06, = 0.67?0.88, = 0.66?0.55, = 0.67?0.67, = 0.74221282_x_at0.42, = 0.90?1.16, = 0.57?0.09, = 0.961.06, = 0.57221283_at0.39, = 0.90?2.08, = 0.22?2.93, = 0.169?0.76, = 0.72236858_s_atn.d.?1.44, = 0.461.58, = 0.36n.d.236859_atn.d.?1.83, = 0.30?2.81, = 0.96n.d. S1PR1 204642_at?3.0, = 0.09* ?3.36, = 0.020.79, = 0.55?1.92, = 0.25 SPP1 209875_s_at?2.11, = 0.28* ?3.30, = 0.02?1.64, = 0.19?1.79, = 0.28 TGF1 203084_at?1.87, = 0.36?0.10, = 0.960.72, = 0.59?1.97, = 0.23203085_s_at?0.52, = 0.860.38, = 0.87* 3.05, = 0.0122.63, = 0.11 TNF 207113_s_at0.33, = 0.92?0.27, = 0.910.61, = 0.650.47, = 0.82 TNFRSF11A = 0.75?1.63, = 0.38?0.62, = 0.640.67, = 0.73238846_atn.d. ?2.69, = 0.08n.d.0.86, = 0.65 TNFRSF11B = 0.69?1.13, = 0.580.77, Bismuth Subsalicylate = 0.560.55, = 0.79204933_s_at1.49, = 0.50?0.35, = 0.88?0.49, = 0.72?0.20, = 0.92 TNFSF11 = 0.881.00, = 0.602.20, = 0.075?0.45, = 0.83 Open in a separate window We addressed the question of which cytokine network components controlling osteoclastogenesis and the formation of OB (summarized in Figure 2a) are affected by FLT3 ITD in blasts and mononuclear cells of AML patients. Open in a separate window MTC1 Open in a separate window Figure 2 Cytokine network controlling bone homeostasis. The schematic depicts the main components involved in differentiation of osteoblasts (OBs) and osteocytes (OCys) derived from mesenchymal stem cells (MSCs) as well as the differentiation of osteoclasts (OCs) derived from haematopoietic stem cells (HSCs) maturated via OC precursor cells (OCPs). (a) Secretory components are Bismuth Subsalicylate framed in yellow, membrane-localized components are indicated in orange. Arrows indicate stimulatory, blocked symbols indicate inhibitory activities. (b) Overview about differentially expressed genes (DEGs) of FLT3 ITD-positive compared to FLT3 WT AML patient samples. Upregulated genes are marked in red (significantly up) or rose (trend of upregulation). Downregulated genes are presented in grey. To illustrate the effect of FLT3 ITD on their gene expression, Figure 2b has an overview of parts with modified DEGs. FLT3 ITD-positive examples showed a solid upregulation from the FLT3 receptor in comparison to FLT3 WT examples (Desk 1, Shape 2b). and RANKL receptor were been shown to be downregulated in FLT3 ITD-positive AML examples preferentially. Upon depletion of M-CSF, the FLT3 ligand FL can compensate its part in osteoclastogenesis [17]. Like M-CSF, FL was downregulated in FLT3 ITD-positive AML examples predominately. The costimulatory receptor OSCAR promotes OC differentiation through activation of NFATc1 [33] also. As opposed to RANK and M-CSF, showed a tendency towards increased manifestation in FLT3 ITD-positive AML examples. As indicated above already, and (and shows decreased osteoimmunological response in FLT3 ITD AML examples. DKK1, that is secreted from adult OBs, implements a poor responses to Wnt/-catenin signalling of OB precursor cells and for that reason downregulates OB development [41,42]. Manifestation of was downregulated in FLT3 ITD-positive AML examples, although only within the Metzeler “type”:”entrez-geo”,”attrs”:”text message”:”GSE12417″,”term_id”:”12417″GSE12417-“type”:”entrez-geo”,”attrs”:”text message”:”GPL96″,”term_id”:”96″GPL96 data arranged was this significant..